^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Entyvio (vedolizumab)

    i
    Other names: LDP 02, MLN 0002, LDP-02, LPD-02, MLN-0002, MLN-002, MLN-02, MLN02, LDP02, MLN0002, LPD 02, LPD02, MLN 002, MLN002, MLN 02
    Associations

    News

    Trials
    Company:
    Takeda
    Drug class:
    α4β7 integrin antagonist
    Related drugs:
    Associations

    News

    Trials
    1d
    Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov)
    P2, N=57, Recruiting, Odyssey Therapeutics | Trial primary completion date: Jan 2026 --> Apr 2026
    Trial primary completion date
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    Entyvio (vedolizumab)
    3d
    The Association Between Interleukin-7 Receptor Gene Polymorphism and the Risk of Ulcerative Colitis (clinicaltrials.gov)
    P4, N=898, Completed, Second Affiliated Hospital of Wenzhou Medical University
    New P4 trial
    |
    Entyvio (vedolizumab)
    8d
    Latent tuberculosis screening for inflammatory bowel disease in tuberculosis endemic region remains porous and suboptimal: A multicentre study. (PubMed, World J Gastroenterol)
    Standard screening practices for LTB, prior to starting advanced therapy, remain suboptimal (< 60%) in India despite high TB endemicity.
    Retrospective data • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    tofacitinib • Entyvio (vedolizumab)
    10d
    Association of tissue lymphocyte immunophenotype and clinical outcomes: A prospective study in patients with ulcerative colitis treated with vedolizumab. (PubMed, PLoS One)
    T cell immunophenotype may be a promising predictive biomarker of vedolizumab treatment efficacy.
    Clinical data • Journal
    |
    CD4 (CD4 Molecule) • KLRB1 (Killer Cell Lectin Like Receptor B1)
    |
    Entyvio (vedolizumab)
    13d
    Impact of Discontinuing Oral Mesalazine on Clinical Remission Response in Ulcerative Colitis Patients in Maintenance Remission Initiating Vedolizumab Therapy: A Multicenter Prospective Randomized Controlled Clinical Study (ChiCTR2500111500)
    P4, N=252, Not yet recruiting, The First Affiliated Hospital of Zhejiang University School of Medicine; The First Affiliated Hospital of Zhejiang University School of Medicine
    New P4 trial
    |
    Entyvio (vedolizumab)
    17d
    NCI-2018-03437: Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer (clinicaltrials.gov)
    P1, N=800, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Entyvio (vedolizumab)
    23d
    AVT80-GL-P01: Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and Entyvio (clinicaltrials.gov)
    P1, N=385, Completed, Alvotech Swiss AG | Active, not recruiting --> Completed
    Trial completion
    |
    Entyvio (vedolizumab)
    29d
    VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease (clinicaltrials.gov)
    P4, N=304, Recruiting, Alimentiv Inc. | Trial completion date: Sep 2028 --> Feb 2029 | Trial primary completion date: Jan 2027 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    Entyvio (vedolizumab)
    1m
    Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease] (clinicaltrials.gov)
    P=N/A, N=335, Active, not recruiting, Takeda | Completed --> Active, not recruiting | Trial completion date: Oct 2025 --> Jun 2026 | Trial primary completion date: Oct 2025 --> Jun 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Entyvio (vedolizumab)
    1m
    Dual biologic therapy in patient with refractory ulcerative colitis and comorbidities: A case report. (PubMed, World J Gastroenterol)
    This case highlighted the challenge of managing refractory UC, especially in frail patients.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    Entyvio (vedolizumab)
    1m
    Endometrial stromal sarcoma in a patient with ulcerative colitis receiving immunosuppressive therapy: A case report and review of literature. (PubMed, World J Clin Cases)
    Patients with inflammatory bowel disease have a higher risk of cancer due to inflammation or treatment. Proper screening with multidisciplinary care can improve outcomes.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    Entyvio (vedolizumab)
    2ms
    EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis (clinicaltrials.gov)
    P2, N=0, Withdrawn, Therakos LLC | N=30 --> 0 | Suspended --> Withdrawn
    Enrollment change • Trial withdrawal • Checkpoint inhibition
    |
    Entyvio (vedolizumab)